ArticleDiscover oncology2026
Identification of MARCKSL1 as an independent prognostic biomarker and analysis of its potential regulatory network in hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) represents a major contributor to cancer-associated mortality globally. Due to the frequently asymptomatic early course and high proportion of late-stage detection, patient outcomes remain unsatisfactory, underscoring the demand for innovative diagnostic markers and treatment approaches. This study was dedicated to characterizing expression profiles and evaluating the prognostic value of myristoylated alanine-rich C kinase substrate-like 1 (MARCKSL1) in HCC. Through integrated analysis of data from the TCGA-LIHC and GSE14520 cohorts alongside in vitro validation, we comprehensively assessed MARCKSL1 expression patterns and their links with clinicopathological parameters. Public cohort analyses showed that MARCKSL1 was significantly upregulated in HCC tissues, and qRT-PCR analysis further supported elevated MARCKSL1 expression in selected HCC cell lines. This upregulated MARCKSL1 expression showed a positive correlation with various poor prognostic clinical factors, namely advanced tumor stage, higher histological grade, and elevated alpha-fetoprotein (AFP) concentration. Moreover, elevated MARCKSL1 expression was linked to reduced overall survival (OS) and disease-specific survival (DSS). A prognostic model built on these observations demonstrated reliable performance in predicting patient survival. Functional annotation analyses implicated MARCKSL1 in essential processes including cell cycle control, and its expression showed a significant association with immune cell infiltration, indicating a potential connection to the tumor immune landscape. Additionally, MARCKSL1 expression correlated with m⁶A methylation markers, suggesting its potential implication in the correlative networks of these epigenetic pathways during HCC development. We also established a predictive competing endogenous RNA (ceRNA) network, identifying key long non-coding RNAs (lncRNAs) that may co-regulate MARCKSL1 via specific microRNAs. Preliminary in vitro assessment supported increased MARCKSL1 transcript expression in selected HCC cell lines. In summary, MARCKSL1 is overexpressed in HCC and closely tied to aggressive clinicopathological traits and inferior prognosis, offering new insights into the evaluation of candidate prognostic biomarkers for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.